RayKnowChina Research Map
Shortlist0

Air Force Medical University

空军军医大学

Xi'anUniversity or health system

Hospitals that carry this university's name, added together, plus papers and trials that name only the university.

Research activity, not treatment quality. Not medical advice. How this works

Nasopharyngeal carcinoma

鼻咽癌
0.2%Leads under 1 in 100 of China's research papers on NPC

Led 5 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.4%).

Run this PubMed search

Open trials led
1
Research papers it led
5
Trials it led
2
Share of China's trials
0.3%
Share of the world's papers
0.1%
Papers led per year
2021: 2220212022: 0020222023: 1120232024: 0020242025: 222025
ThemesRadiotherapy techniqueImaging & AIRecurrent / metastatic disease

Hospitals counted here

  1. Xijing Hospital4
  2. First Affiliated Hospital of Air Force Medical University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. A predictive model based on the dosimetric parameters of the parotid stem cell region to assess the recovery of radiation-induced xerostomia in long-term survivors of nasopharyngeal carcinoma after radical radiotherapy.2025Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  2. A novel multimodal adaptive delineation model for primary tumors and lymph node metastases in multi-center nasopharyngeal carcinoma radiotherapy.2025Computer methods and programs in biomedicine
  3. Therapeutic Evaluation of Induction Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma With Low-risk N Stage : A Multicenter Retrospective Study From Nonendemic Region of China.2023American journal of clinical oncology
  4. Detailed analysis of recovery process of cranial nerve palsy after IMRT-based comprehensive treatment in nasopharyngeal carcinoma.2021Radiation oncology (London, England)Free full text
  5. Prognostic analysis of 152 patients with distant metastasis after intensity-modulated radiotherapy for nasopharyngeal carcinoma.2021Annals of palliative medicine
Trials on ClinicalTrials.gov6
  1. GNT Induction Treatment in Locally Advanced NPCRecruitingNCT06026878Lead sponsorPhase 3Start 2023-09
  2. Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III TrialRecruitingNCT05340491Study sitePhase 3Start 2022-04
  3. PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma PatientsRecruitingNCT03907826Study sitePhase 3Start 2020-03
  4. GP VS TP in the Treatment of Advanced Nasopharyngeal Carcinoma in Northwest ChinaCompletedNCT01596868Lead sponsorPhase 2Start 2012-05
  5. PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal CarcinomaStatus unknownNCT03427827Study sitePhase 3Start 2018-07
  6. Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal CarcinomaStatus unknownNCT03700476Study sitePhase 3Start 2018-12

PubMed searchClinicalTrials.gov

Oesophageal squamous cell carcinoma

食管鳞状细胞癌
1.3%Leads about 1 in 79 of China's research papers on ESCC ▲ from 0.6%

Led 37 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.9%).

Run this PubMed search

Open trials led
7
Research papers it led
37
Trials it led
12
Share of China's trials
2.1%
Share of the world's papers
0.9%
Papers led per year
2021: 0020212022: 3320222023: 1120232024: 0020242025: 112025
ThemesNeoadjuvant & combined treatmentRadiotherapyMolecular markers & genomics

Hospitals counted here

  1. Xijing Hospital21
  2. Tangdu Hospital13
  3. First Affiliated Hospital of Air Force Medical University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Pre-procedure oral administration of pronase improves efficacy of lugol chromoendoscopy in esophageal squamous cell carcinoma screening: a prospective, double-blinded, randomized, controlled trial.2023Surgical endoscopyRCT
  2. CT-based radiomics nomogram may predict local recurrence-free survival in esophageal cancer patients receiving definitive chemoradiation or radiotherapy: A multicenter study.2022Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and OncologyRCT
  3. Clinical benefit of tunnel endoscopic submucosal dissection for esophageal squamous cancer: a multicenter, randomized controlled trial.2022Gastrointestinal endoscopyRCT
  4. Comparing N-acetylcysteine with sodium thiosulfate for relieving symptoms caused by Lugol's iodine chromoendoscopy: a randomized, double-blind trial.2022Gastrointestinal endoscopyRCT
  5. Four-year follow-up from the phase 2 study TD-NICE: neoadjuvant treatment of tislelizumab combined with chemotherapy in resectable esophageal squamous cell carcinoma.2025BMC cancerFree full text
Trials on ClinicalTrials.gov6
  1. A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCCRecruitingNCT07385001Lead sponsorPhase 1/Phase 2Start 2026-01
  2. Neoadjuvant Treatment of Toripalimab Combined With Nab-paclitaxel and Platinum Versus Neoadjuvant Docetaxel Combined With Cisplatin and 5-fluorouracil (DCF) in Esophageal Squamous Cell CarcinomaNot yet recruitingNCT06952621Lead sponsorPhase 3Start 2026-02
  3. Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCCRecruitingNCT07452601Lead sponsorPhase 2Start 2026-05
  4. Retlirafusp Alfa Plus Chemotherapy as Neoadjuvant Therapy for Thoracic ESCCNot yet recruitingNCT07618910Lead sponsorPhase 2Start 2026-05
  5. Neoadjuvant Short-Course Radiotherapy Plus Tislelizumab and Chemotherapy for Locally Advanced Resectable Esophageal Squamous Cell CarcinomaNot yet recruitingNCT07678580Lead sponsorPhase 2Start 2026-07
  6. Adebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles StudyRecruitingNCT06663059Lead sponsorPhase 2Start 2024-10

PubMed searchClinicalTrials.gov

Hepatocellular carcinoma

肝细胞癌
0.7%Leads under 1 in 100 of China's research papers on HCC ▼ from 1.2%

Led 99 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (5.5%).

Run this PubMed search

Open trials led
1
Research papers it led
99
Trials it led
9
Share of China's trials
0.6%
Share of the world's papers
0.4%
Papers led per year
2021: 2220212022: 1120222023: 1120232024: 0020242025: 112025
ThemesRecurrence & prognosisImaging, AI & early detectionImmunotherapy & targeted drugs

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Xijing Hospital54
  2. Tangdu Hospital16
  3. First Affiliated Hospital of Air Force Medical University Counted in the group total3
  4. Air Force Medical Center2
  5. Xijng Hospital, Fourth Military Medical University2
  6. First Affiliated Hospital of Air Force Military Medical University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. CXCL12+ tumor-associated endothelial cells promote immune resistance in hepatocellular carcinoma.2025Journal of hepatology
  2. HMMR alleviates endoplasmic reticulum stress by promoting autophagolysosomal activity during endoplasmic reticulum stress-driven hepatocellular carcinoma progression.2023Cancer communications (London, England)Free full text
  3. Increased mitochondrial fission drives the reprogramming of fatty acid metabolism in hepatocellular carcinoma cells through suppression of Sirtuin 1.2022Cancer communications (London, England)Free full text
  4. GDF15 induces immunosuppression via CD48 on regulatory T cells in hepatocellular carcinoma.2021Journal for immunotherapy of cancerFree full text
  5. UBE2S interacting with TRIM28 in the nucleus accelerates cell cycle by ubiquitination of p27 to promote hepatocellular carcinoma development.2021Signal transduction and targeted therapyFree full text
Trials on ClinicalTrials.gov6
  1. Efficacy and Safety of SIRT-Y90 in Combination With Atezo + Bev for Unresectable Hepatocellular CarcinomaRecruitingNCT07610551Lead sponsorStart 2022-02
  2. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.RecruitingNCT05862337Study sitePhase 3Start 2023-05
  3. Liver Resection for Patients With Hepatocellular Carcinoma and Impaired Liver FunctionCompletedNCT06245785Lead sponsorStart 2023-01
  4. Liver Resection for Patients With Hepatocellular Carcinoma and Clinically Significant Portal HypertensionCompletedNCT06245798Lead sponsorStart 2023-01
  5. Drug-eluting Bead Transarterial Chemoembolisation (DEB-TACE) Versus (VS) Conventional Transarterial Chemoembolisation (cTACE) for Unresectable Hepatocellualr Carcinoma (HCC)Status unknownNCT03969576Lead sponsorN/AStart 2020-09
  6. A Study of CD147-targeted CAR-T by Hepatic Artery Infusions for Very Advanced Hepatocellular CarcinomaStatus unknownNCT03993743Lead sponsorPhase 1Start 2019-05

PubMed searchClinicalTrials.gov

Stomach cancer

胃癌
0.8%Leads under 1 in 100 of China's research papers on Stomach cancer ▼ from 1.5%

Led 77 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (3.9%).

Run this PubMed search

Open trials led
8
Research papers it led
77
Trials it led
36
Share of China's trials
2.5%
Share of the world's papers
0.4%
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 332025
ThemesPeritoneal spread & advanced diseaseSurgeryImmunotherapy & targeted drugs

Hospitals counted here

  1. Xijing Hospital59
  2. Tangdu Hospital9
  3. Second Affiliated Hospital of Air Force Medical University Counted in the group total5
  4. First Affiliated Hospital of Air Force Medical University Counted in the group total3
  5. First Affiliated Hospital of Air Force Military Medical University Counted in the group total1
  6. Air Force Medical Center1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Main results of a randomized controlled trial (RNPLS-01): efficacy and safety of ramucirumab combined with nab-paclitaxel, lobaplatin, and S-1 in neoadjuvant therapy for advanced gastric cancer.2025International journal of surgery (London, England)RCTFree full text
  2. A prospective randomized study of the efficacy of continuous active warming in patients undergoing laparoscopic gastrectomy.2025BMC gastroenterologyRCTFree full text
  3. A novel method of bedside hyperthermic intraperitoneal chemotherapy as adjuvant therapy for stage-III gastric cancer.2022International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia GroupRCT
  4. Total Laparoscopic Uncut Roux-en-Y for Radical Distal Gastrectomy: An Interim Analysis of a Randomized, Controlled, Clinical Trial.2021Annals of surgical oncologyRCT
  5. Diagnostic efficacy of an extracellular vesicle-derived lncRNA-based liquid biopsy signature for the early detection of early-onset gastric cancer.2025Gut
Trials on ClinicalTrials.gov6
  1. Evaluation of Fecal Multi-target Biomarkers in the Screening of Digestive Tract CancersRecruitingNCT07600125Lead sponsorStart 2026-08
  2. Full-time RDI for ESD: Impact on Major Adverse Events and Procedure TimeRecruitingNCT07401303Lead sponsorN/AStart 2026-03
  3. A Clinical Study Comparing Anti-HER2 Therapy Combined With Chemotherapy to Chemotherapy Alone as Adjuvant Therapy Following Surgery for Stage IB-II Gastric Cancer With High HER2 Expression.RecruitingNCT07788196Lead sponsorPhase 2Start 2026-07
  4. Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label StudyNot yet recruitingNCT07685704Lead sponsorPhase 2Start 2026-07
  5. Investigating Multigene Methylation Dynamics in Treatment Response Surveillance for Gastric CancerRecruitingNCT06979895Lead sponsorStart 2025-05
  6. Therapeutic Study of 177Lu-CTR-FAPI in Advanced Metastatic Digestive MalignanciesNot yet recruitingNCT07014254Lead sponsorN/AStart 2025-06

PubMed searchClinicalTrials.gov

Hepatoblastoma

肝母细胞瘤
1.3%Leads about 1 in 77 of China's research papers on Hepatoblastoma New since 2021

Led 2 of 154 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (13.6%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

Hospitals counted here

  1. Tangdu Hospital1
  2. Xijing Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Osteosarcoma

骨肉瘤
1.1%Leads about 1 in 94 of China's research papers on Osteosarcoma

Led 24 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
24
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 2220222023: 3320232024: 0020242025: 002025

PubMed searchClinicalTrials.gov

Gastrointestinal stromal tumour

胃肠道间质瘤
0.8%Leads under 1 in 100 of China's research papers on Gastrointestinal stromal tumour ▼ from 3.7%

Led 4 of 523 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.3%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
1
Share of China's trials
1.4%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 332025

Hospitals counted here

  1. Xijing Hospital4

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Neuroblastoma

神经母细胞瘤
0.3%Leads under 1 in 100 of China's research papers on Neuroblastoma

Led 3 of 1,132 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.8%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.07%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 1120242025: 002025

Hospitals counted here

  1. Xijing Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Ewing sarcoma

尤文肉瘤
1.2%Leads about 1 in 81 of China's research papers on Ewing sarcoma New since 2021

Led 2 of 163 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.6%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

Hospitals counted here

  1. Xijing Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Multiple myeloma

多发性骨髓瘤
0.2%Leads under 1 in 100 of China's research papers on Myeloma ▼ from 0.8%

Led 3 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.8%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
1
Share of China's trials
0.2%
Share of the world's papers
0.03%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 112025
ThemesDiagnosis, MRD & riskKidney & bone complications

Hospitals counted here

  1. Xijing Hospital2
  2. Second Affiliated Hospital of Air Force Medical University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led3
  1. Development and validation of a novel frailty model for the patients with newly diagnosed multiple myeloma.2025European journal of medical researchFree full text
  2. Lambda light chain - restricted non - crystalline proximal tubulopathy with cast nephropathy in multiple myeloma: a case report and literature review.2024BMC nephrologyFree full text
  3. Analysis of coagulation alteration and its correlation with β2-microglobulin in 371 patients with newly diagnosed multiple myeloma.2024Hematology (Amsterdam, Netherlands)
Trials on ClinicalTrials.gov6
  1. Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma PatientsRecruitingNCT07663253Study siteStart 2026-06
  2. A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple MyelomaStatus unknownNCT04182581Lead sponsorEarly phase 1Start 2019-10
  3. ATG-010(Selinexor) in Combination With Chemotherapy in RRMMStatus unknownNCT04877275Study sitePhase 2Start 2021-05
  4. A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple MyelomaCompletedNCT03944057Study sitePhase 2Start 2019-09
  5. A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)CompletedNCT03217812Study sitePhase 3Start 2017-11
  6. A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT03234972Study sitePhase 3Start 2017-11

PubMed searchClinicalTrials.gov

B-cell acute lymphoblastic leukaemia (B-ALL)

B 细胞急性淋巴细胞白血病
1.3%Leads about 1 in 75 of China's research papers on B-ALL New since 2021

Led 3 of 225 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.9%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
2
Share of China's trials
0.8%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 332025
ThemesStem cell transplantPhiladelphia chromosome & genetics

Hospitals counted here

  1. Xijing Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Haemophagocytic lymphohistiocytosis (HLH)

噬血细胞性淋巴组织细胞增生症
0.5%Leads under 1 in 100 of China's research papers on HLH New since 2021

Led 2 of 399 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (22.3%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
ThemesEBV & infection triggersDiagnosis & prognosis

Hospitals counted here

  1. Tangdu Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Neuromyelitis optica spectrum disorder (NMOSD)

视神经脊髓炎谱系疾病
1.2%Leads about 1 in 81 of China's research papers on NMOSD ▲ from 0.4%

Led 6 of 485 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.5%).

Run this PubMed search

Open trials led
3
Research papers it led
6
Trials it led
3
Share of China's trials
3.9%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 1120222023: 2220232024: 1120242025: 112025
ThemesBiologic drugsAntibodies & diagnosisRelapse prevention

Hospitals counted here

  1. Tangdu Hospital5

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Long-term efficacy and safety of low-dose rituximab strategy in neuromyelitis optica spectrum disorder: a retrospective cohort study on treatment compliance and clinical outcomes.2025Orphanet journal of rare diseasesFree full text
  2. Rituximab at lower dose for neuromyelitis optica spectrum disorder: a multicenter, open-label, self-controlled, prospective follow-up study.2023Frontiers in immunologyFree full text
  3. Emerging trends and research foci of neuromyelitis optica spectrum disorder: a 20-year bibliometric analysis.2023Frontiers in immunologyFree full text
  4. Expression of CD226 is upregulated on Tr1 cells from neuromyelitis optica spectrum disorder patients.2022Brain and behaviorFree full text
  5. CD22 blockade exacerbates neuroinflammation in Neuromyelitis optica spectrum disorder.2024Journal of neuroinflammationFree full text
Trials on ClinicalTrials.gov6
  1. Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory TrialNot yet recruitingNCT07699770Lead sponsorPhase 4Start 2026-06
  2. Efficacy and Safety of Transcranial Temporal Interference Stimulation (tTIS) for Neuropathic Pain in Neuromyelitis Optica Spectrum Disorder (NMOSD)RecruitingNCT07377305Lead sponsorN/AStart 2025-12
  3. Ofatumumab in AQP4-IgG Seropositive NMOSDRecruitingNCT05504694Lead sponsorPhase 1/Phase 2Start 2022-06
  4. A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)RecruitingNCT06413654Study sitePhase 2/Phase 3Start 2024-07
  5. Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)RecruitingNCT05145361Study siteEarly phase 1Start 2022-04
  6. A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum DisordersActive, not recruitingNCT06044350Study sitePhase 2Start 2023-08

PubMed searchClinicalTrials.gov

Myasthenia gravis

重症肌无力
4.4%Leads about 1 in 23 of China's research papers on Myasthenia gravis

Led 22 of 499 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.6%).

Run this PubMed search

Open trials led
3
Research papers it led
22
Trials it led
7
Share of China's trials
7.6%
Share of the world's papers
1.0%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 332025
ThemesThymus & thymectomyAntibodies & diagnosisBiologic & complement drugs

Hospitals counted here

  1. Tangdu Hospital19
  2. Second Affiliated Hospital of Air Force Medical University1
  3. Second Affiliated Hospital of Air Force Military Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Association between antibody status and exacerbation in patients with myasthenia gravis who achieved minimal manifestation or better status.2025Journal of neurology
  2. Efficacy and safety of efgartigimod versus intravenous immunoglobulin in early intervention of acetylcholine receptor antibody-positive impending myasthenic crisis: A retrospective cohort study.2025Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeuticsFree full text
  3. Efficacy and Safety of Efgartigimod for Patients With Myasthenia Gravis in a Real-World Cohort of 77 Patients.2025CNS neuroscience & therapeuticsFree full text
  4. Tocilizumab for the management of corticosteroid-resistant GO combined with OMG: a case series.2024BMC ophthalmologyFree full text
  5. Efficacy and safety of tocilizumab in patients with refractory generalized myasthenia gravis.2024CNS neuroscience & therapeuticsFree full text
Trials on ClinicalTrials.gov6
  1. Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia GravisRecruitingNCT06371040Lead sponsorPhase 1Start 2024-07
  2. Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia GravisRecruitingNCT05067348Lead sponsorPhase 2Start 2022-07
  3. TheRapeutic Effect of Different immunosuppressAnts on Non-Thymoma Ocular Myasthenia Gravis: a Real-world StudyRecruitingNCT04182984Lead sponsorStart 2019-11
  4. A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.RecruitingNCT06447597Study sitePhase 2/Phase 3Start 2024-07
  5. Myasthenia Gravis Registry in ChinaRecruitingNCT06241521Study siteStart 2024-02
  6. A Study of Nipocalimab Administered to Adults With Generalized Myasthenia GravisRecruitingNCT04951622Study sitePhase 3Start 2021-07

PubMed searchClinicalTrials.gov

Moyamoya disease

烟雾病
0.6%Leads under 1 in 100 of China's research papers on Moyamoya

Led 2 of 356 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (19.9%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025
ThemesImaging & blood flowRevascularisation surgery

Hospitals counted here

  1. Xijing Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎
1.5%Leads about 1 in 66 of China's research papers on Anti-NMDA receptor encephalitis New since 2021

Led 4 of 264 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.2%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 1120242025: 112025

Hospitals counted here

  1. Xijing Hospital3
  2. Tangdu Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Takayasu arteritis

大动脉炎
1.6%Leads about 1 in 62 of China's research papers on Takayasu arteritis ▼ from 2.2%

Led 3 of 187 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (24.6%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 112025

Hospitals counted here

  1. Xijing Hospital3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Idiopathic pulmonary fibrosis

特发性肺纤维化
0.3%Leads under 1 in 100 of China's research papers on Idiopathic pulmonary fibrosis

Led 3 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.08%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 222025

Hospitals counted here

  1. Xijing Hospital1
  2. Tangdu Hospital1
  3. Second Affiliated Hospital of Air Force Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

IgA nephropathy

IgA 肾病
1.4%Leads about 1 in 74 of China's research papers on IgA nephropathy

Led 10 of 736 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
0
Research papers it led
10
Trials it led
4
Share of China's trials
3.4%
Share of the world's papers
0.6%
Papers led per year
2021: 2220212022: 3320222023: 0020232024: 0020242025: 002025

Hospitals counted here

  1. Xijing Hospital10

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Expansion of Escherichia-Shigella in Gut Is Associated with the Onset and Response to Immunosuppressive Therapy of IgA Nephropathy.2022Journal of the American Society of Nephrology : JASNRCT
  2. The clinicopathological characteristics and outcomes of IgA nephropathy with predominant lambda or kappa light-chain deposition.2022International urology and nephrology
  3. Long-term outcomes of IgA nephropathy patients with less than 25% crescents and mild proteinuria.2022Clinical and experimental nephrology
  4. The prognostic effect of immunosuppressive therapy in IgA nephropathy with stage 3 or 4 chronic kidney disease.2021Renal failure
  5. Alleviation of refractory IgA nephropathy by intensive fecal microbiota transplantation: the first case reports.2021Renal failure
Trials on ClinicalTrials.gov5
  1. Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgANRecruitingNCT07390123Study sitePhase 3Start 2026-04
  2. Efficacy and Safety of CD19 CAR-γδ T Cells in the Treatment of Relapsed/Refractory Autoimmune NephropathyNot yet recruitingNCT07535138Lead sponsorEarly phase 1Start 2026-05
  3. Exploring the Brain - Gut Microbiota - Kidney Interactive Damage Mechanisms Underlying Cognitive Decline in Patients With IgA Nephropathy Using Ultra-high Field Magnetic Resonance ImagingCompletedNCT07617402Lead sponsorStart 2025-04
  4. Efficacy of Immunosuppressive Therapy for IgA Nephropathy With Stage 3 or 4 CKDRecruitingNCT05510323Lead sponsorPhase 3Start 2024-02
  5. Fecal Microbiota Transplantation for Refractory IgA NephropathyStatus unknownNCT03633864Lead sponsorPhase 2Start 2017-11

PubMed searchClinicalTrials.gov

Primary biliary cholangitis

原发性胆汁性胆管炎
5.7%Leads about 1 in 18 of China's research papers on Primary biliary cholangitis ▲ from 1.3%

Led 17 of 300 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
6
Research papers it led
17
Trials it led
13
Share of China's trials
26.0%
Share of the world's papers
1.7%
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 0020242025: 332025

Hospitals counted here

  1. Xijing Hospital17

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Effectiveness of Fenofibrate in Treatment-Naive Patients With Primary Biliary Cholangitis: A Randomized Clinical Trial.2023The American journal of gastroenterologyRCT
  2. Prediction and evaluation of high-risk patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy: an early criterion.2023Hepatology internationalRCT
  3. The Treatment of Primary Biliary Cholangitis: Time for Personalized Medicine.2025Clinical reviews in allergy & immunology
  4. Risk stratification for patients with primary biliary cholangitis: early versus advanced-stage or non-cirrhosis versus cirrhosis?2025Hepatology international
  5. The prognostic value of anti-gp210 and anti-centromere antibodies in patients with primary biliary cholangitis: Enhancing the prognostic utility on the GLOBE scoring system.2025Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Trials on ClinicalTrials.gov6
  1. FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC TherapyRecruitingNCT07296458Lead sponsorPhase 3Start 2025-12
  2. Fenofibrate in Primary Biliary Cholangitis: a Real World StudyRecruitingNCT06755151Lead sponsorPhase 3Start 2024-01
  3. Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis: a Real World StudyRecruitingNCT06755541Lead sponsorPhase 3Start 2024-01
  4. Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary CholangitisRecruitingNCT05749822Lead sponsorPhase 2/Phase 3Start 2023-02
  5. Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary CholangitisRecruitingNCT05751967Lead sponsorPhase 3Start 2023-02
  6. Fenofibrate in Patients With Primary Biliary Cholangitis (PBC)RecruitingNCT06365424Lead sponsorPhase 2/Phase 3Start 2017-04

PubMed searchClinicalTrials.gov

Familial adenomatous polyposis

家族性腺瘤性息肉病
0.0%Leads none of China's research papers on Familial adenomatous polyposis

Led 0 of 59 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.2%).

Run this PubMed search

Open trials led
0
Research papers it led
0
Trials it led
1
Share of China's trials
33.3%
Share of the world's papers
0.0%
Trials on ClinicalTrials.gov1
  1. Primary Chemoprevention of Familial Adenomatous Polyposis With Berberine HydrochlorideCompletedNCT03333265Lead sponsorPhase 2/Phase 3Start 2017-09

PubMed searchClinicalTrials.gov